Anemia is the most common complication of chronic kidney disease (CKD) and the main cause of poor prognosis in CKD patients. Iron deficiency (ID) is the second most important factor in the occurrence of anemia in CKD besides EPO deficiency, and iron is currently the main treatment for iron deficiency in patients with CKD anemia. Iron supplements are divided into intravenous iron and oral iron supplements. Oral iron is often ineffective due to its gastrointestinal side effects and low absorption efficiency. Traditional intravenous iron can only be administered in small single doses due to safety restrictions. New intravenous iron agents have emerged. This article provides a brief overview of current iron metabolism in chronic kidney disease, causes of iron deficiency, iron status and new intravenous iron agents available.

Chuying Zhao, Ying Li. Iron deficiency in chronic kidney disease and the new generation of intravenous iron. Frontiers in Medical Science Research (2023) Vol. 5, Issue 4: 18-22. https://doi.org/10.25236/FMSR.2023.050403.

[1] ZHANG L, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet (London, England), 2012, 379(9818): 815-22.

[2] Foundation N K. II. Clinical practice guidelines and clinical practice recommendations for Anemia in Chronic Kidney disease in adults[J]. American journal of kidney diseases: the official journal of the National Kidney Foundation, 2006, 47(5 Suppl 3): S16-S85.

[3] ZAGER R A. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease [J]. Clinical journal of the American Society of Nephrology : CJASN, 2006, 1 (Suppl 1)S24-31.

[4] BABITT J L, LIN H Y. Mechanisms of anemia in CKD [J]. Journal of the American Society of Nephrology : JASN, 2012, 23(10): 1631-4.

[5] HENTZE M W, MUCKENTHALER M U, GALY B, et al. Two to tango: regulation of Mammalian iron metabolism [J]. Cell, 2010, 142(1): 24-38.

[6] NICOLAS G, BENNOUN M, DEVAUX I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice [J]. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(15): 8780-5.

[7] GANZ T, NEMETH E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease [J]. Seminars in nephrology, 2016, 36(2): 87-93.

[8] MAZUR A, FEILLET-COUDRAY C, ROMIER B, et al. Dietary iron regulates hepatic hepcidin 1 and 2 mRNAs in mice [J]. Metabolism: clinical and experimental, 2003, 52(10): 1229-31.

[9] SHAH Y M, XIE L. Hypoxia-inducible factors link iron homeostasis and erythropoiesis [J]. Gastroenterology, 2014, 146(3): 630-42.

[10] NEMETH E, VALORE E V, TERRITO M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein [J]. Blood, 2003, 101(7): 2461-3.

[11] NICOLAS G, CHAUVET C, VIATTE L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation [J]. The Journal of clinical investigation, 2002, 110(7): 1037-44.

[12] VAN DER WEERD N C, GROOTEMAN M P, BOTS M L, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents [J]. PloS one, 2012, 7(7): e39783.

[13] BAZELEY J W, WISH J B. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review [J]. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022, 79(6): 868-76.

[14] YANG J Y, LEE T C, MONTEZ-RATH M E, et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients [J]. Journal of the American Society of Nephrology : JASN, 2012, 23(3): 495-506.

[15] LIANG C C, WANG S M, KUO H L, et al. Upper gastrointestinal bleeding in patients with CKD [J]. Clinical journal of the American Society of Nephrology : CJASN, 2014, 9(8): 1354-9.

[16] BABITT J L, EISENGA M F, HAASE V H, et al. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference [J]. Kidney international, 2021, 99(6): 1280-95.

[17] AGARWAL R. Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions [J]. Hemodialysis international International Symposium on Home Hemodialysis, 2017, 21 Suppl 1(S78-s82.

[18] AUERBACH M, STRAUSS W, AUERBACH S, et al. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min [J]. American journal of hematology, 2013, 88(11): 944-7.

[19] HUANG Y, HSU J C, KOO H, et al. Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle [J]. Theranostics, 2022, 12(2): 796-816.

[20] LU M, COHEN M H, RIEVES D, et al. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease [J]. American journal of hematology, 2010, 85(5): 315-9.

[21] BALAKRISHNAN V S, RAO M, KAUSZ A T, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation [J]. European journal of clinical investigation, 2009, 39(6): 489-96.

[22] PROVENZANO R, SCHILLER B, RAO M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients [J]. Clinical journal of the American Society of Nephrology : CJASN, 2009, 4(2): 386-93.

[23] MACDOUGALL I C, STRAUSS W E, MCLAUGHLIN J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD [J]. Clinical journal of the American Society of Nephrology : CJASN, 2014, 9(4): 705-12.

[24] STRAUSS W E, DAHL N V, LI Z, et al. Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia [J]. BMC hematology, 2016, 16(20).

[25] AUERBACH M, COYNE D, BALLARD H. Intravenous iron: from anathema to standard of care [J]. American journal of hematology, 2008, 83(7): 580-8.

[26] BLUMENSTEIN I, SHANBHAG S, LANGGUTH P, et al. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety [J]. Expert opinion on drug safety, 2021, 20(7): 757-69.

[27] ONKEN J E, BREGMAN D B, HARRINGTON R A, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial [J]. Nephrology Dialysis Transplantation, 2014, 29(4): 833-42.

[28] MACDOUGALL I C, BOCK A H, CARRERA F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia [J]. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2014, 29(11): 2075-84.

[29] HOES M F, GROTE BEVERBORG N, KIJLSTRA J D, et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function [J]. European journal of heart failure, 2018, 20(5): 910-9.

[30] BHANDARI S, KALRA P A, BERKOWITZ M, et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial [J]. Nephrology Dialysis Transplantation, 2021, 36(1): 111-20.